drugset / Trial / NCT03627390
BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
Phase 2
Completed
16 enrolled
Meabco A/S
Meddoc · collabNorwegian University of Life Sciences · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to investigate the short-term effect and tolerability BP-C1 in patients with metastatic pancreatic cancer who has undergone guideline-recommended chemotherapy.
Timeline
- Start
- 2014-12-19
- Primary completion
- 2016-03-04
- Completion
- 2016-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP-C1 | Other / unclassified | 0.035 mg/kg | Intramuscular |
| Subject | BP-C2 | Other / unclassified | 15 ml | Oral |